China Lifts Import Duties On Human Immunoglobulin And Vaccine
This article was originally published in PharmAsia News
China's Ministry of Finance announced that the current 3 percent import duties on antiserum, human vaccines, cultured microorganisms (excluding yeast) and four types of related immunoglobulins is now lifted effective June 1 through Dec. 31. Even though the adjustment will reduce import costs, analysts see limited impact because local enterprises dominate the domestic vaccine business, while the low-priced immunoglobulin market will not attract MNCs. Many industry experts believe the policy mainly aims to meet the demands of the recent earthquake relief. However, according to the China Chamber of Commerce of Medicines & Health Products Importers & Exporters, the government's original intention is to alleviate the supply-demand conflict of products caused by a rising consumer price index. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.